



ASH 2023

65th ASH Annual Meeting and Exposition

December 9–12, 2023
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in MPN.

ASH 2023: Top abstracts in MPN

December 9–12, 2023

Saturday, December 9

Abstract	Title	
1792 View	Use of combination therapies including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients	Min Lu
1794 View	Combinatorial BCL-2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis	Giacomo Coltro

Sunday, December 10

Abstract	Title	
619 View	Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: Pre-specified interim analysis of the randomized phase 2b ruxobeat clinical trial of the German Study Group for myeloproliferative neoplasms (GSG-MPN)	Steffen Koschmieder
620 View	Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis	Naveen Pemmaraju
622 View	Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-Naïve patients with myelofibrosis: long term follow up from XPORT-MF-034 suggestive of disease modification	Srinivas K. Tantravahi
628 View	Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study	Raajit K. Rampal
3158 View	Modulation of biomarkers by BET Inhibitor, BMS-986158, including JAK2 variant allele frequency (VAF), bone marrow (BM) fibrosis, and reversal of abnormal cytokine production in intermediate- or high-risk myelofibrosis (MF)	Si Tuen Lee-Hoeflich
3204 View	Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: Results from the phase 3 randomized FREEDOM2 study	Claire N Harrison
3207 View	Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis	Helen Ajufu

Monday, December 11

Abstract	Title	
746 View	Final analysis of the Daliah Trial: A randomized phase III trial of interferon- α versus hydroxyurea in patients with MPN	Trine Alma Knudsen
748 View	Impact of Cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and polycythemia vera	Claire N Harrison
4533 View	Prognostic significance and clinical correlations of myeloid mutations in myelofibrosis based on their functional class	Paola Guglielmelli
5174 View	Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the Expanded-Access Jump study	Vikas Gupta



ASH 2023

Follow us on X to keep up to date
with the latest from the congress

@MPN_Hub

#ASH23

View all @MPN_Hub tweets from #ASH23



Brought to you by

